好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Poor Atrial Fibrillation Management Leads to Avoidable Thrombectomies in Elderly Patients
Cerebrovascular Disease and Interventional Neurology
S53 - Stroke Prevention (3:30 PM-3:42 PM)
001

We sought to identify the proportion of avoidable mechanical thrombectomy (MT) procedures in elderly patients (age ≥70 years) with stroke due to atrial fibrillation (AF). 

A significant proportion of MTs for large vessel occlusion (LVO) stroke are avoidable with improved oral anticoagulant (OAC) use in patients with AF. 

This study included 348 consecutive MT cases at a high-volume stroke center from Feb 2015 to Sept 2018. A retrospective chart review was conducted to identify patient sociodemographics, presence of AF, use of anticoagulation, stroke severity, CHA2DS2-VASc scores, and functional outcome.

A total of 191 (55%) patients were ≥70 years (mean age 81±7, 61% female), of which 116 (61%) had AF (median age 82±6, 67% female). Elderly patients with AF were more likely to have hypertension and heart failure and be on antiplatelets and OACs. Pre-existing AF was present in 75 (39%) patients, of which 38 (49%) were not on OACs prior to stroke. Of the 39 (51%) patients with known AF on OACs, 10 (68%) had subtherapeutic INR levels and 5 (21%) were not adherent to direct OACs. Overall, 53/191 (28%) patients with known AF were not adequately anticoagulated prior to the index stroke. There was no significant difference in modified Rankin Scale score at discharge or rate of symptomatic intracerebral hemorrhage between the two groups. 

In our study, about 1 in 4 elderly patients with known AF were not adequately anticoagulated prior to stroke and underwent potentially avoidable thrombectomy. Better practice strategies are needed to increase OAC utilization and adherence to reduce the burden of stroke in patients with AF, especially in elderly women.  

Authors/Disclosures
Nicole B. Sur, MD (University of Miami)
PRESENTER
Dr. Sur has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Stroke. The institution of Dr. Sur has received research support from Florida Stroke Registry. The institution of Dr. Sur has received research support from Miami CTSI & NIH/NINDS.
Vasu Saini, MD (Mount Sinai Medical Center) Dr. Saini has nothing to disclose.
Luis F. Torres, MD (Vivian L Smith Department of Neurosurgery) Dr. Torres has nothing to disclose.
Nastajjia Krementz, MD (Vascular Neurology - University of Miami/Jackson Health System) Dr. Krementz has nothing to disclose.
Sishir Mannava, MD (UT Health) Dr. Mannava has nothing to disclose.
Kunakorn Atchaneeyasakul, MD (Jackson Memorial Hospital) No disclosure on file
Amer Malik, MD (University of Miami Miller School of Medicine) Dr. Malik has nothing to disclose.
Dileep R. Yavagal, MD, FAAN (University of Miami Miller School of Medicine) Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vascular Dynamics. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Guidepoint. The institution of Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Medtronic. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Cerenovus/Johnson & Johnson. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Stryker. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Poseydon. Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Athersys. Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gravity Medical Technology. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Poseydon. Dr. Yavagal has stock in Poseydon. Dr. Yavagal has stock in Galaxy Therapeutics. Dr. Yavagal has stock in Stentrode. Dr. Yavagal has stock in Gravity Medical. Dr. Yavagal has stock in Gravity Medical Technology. Dr. Yavagal has stock in Athersys. Dr. Yavagal has stock in Rapid Medical . Dr. Yavagal has received intellectual property interests from a discovery or technology relating to health care. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Expert with Royal Carribean Cruise Line. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Consultant with Carnival Cruise Line.
Seemant Chaturvedi, MD, FAHA, FAAN (University of Maryland) Dr. Chaturvedi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca. Dr. Chaturvedi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for University of Calgary. Dr. Chaturvedi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. Dr. Chaturvedi has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Ramar & Paradiso. Dr. Chaturvedi has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Cole, Scott, Kissane. The institution of Dr. Chaturvedi has received research support from NINDS.